Hemab Therapeutics Holdings Inc. Common Stock
Financials
Valuation Metrics
Hemab Therapeutics Holdings Inc. Common Stock's Market Cap is $1.89B. Ranked #2056 of 3,115 in US market (top 66%), #788 of 1,472 on NASDAQ (top 54%) by Market Cap.
Investment Metrics(as of 2026-10-29)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $1.89B | US#2,056/3,115 |
| Revenue | $0.00 | US#2,861/3,115 |
| Net Income | $-64M | US—/3,115 |
| Total Assets | $195M | US#2,987/3,115 |
| Net Assets | $-177M | US#2,972/3,115 |
| Employees | 59 | US#2,684/3,115 |
| Value | ||
| FCF Yield | -3.26% | US—/3,115 |
| Profitability | ||
| ROA | -32.81% | US#2,897/3,115 |
| Financial Health | ||
| Total Debt | $1M | US#2,967/3,115 |
| FCF | $-61M | US#2,553/3,115 |
| Cash | $88M | US#2,299/3,115 |
| Current Ratio | 18.03x | US#130/3,115 |
| Performance | ||
| 1M Return | 23.99% | US#291/3,115 |
| From 52W High | -27.07% | US#1,993/3,115 |
| 1Y MDD | -48.36% | US#2,338/3,115 |
| Trading | ||
| Volume | 1,191,567 shares | US#2,195/3,115 |
| Trading Value | $48M | US#2,028/3,115 |
| Per Share | ||
| EPS | $-1.37 | US—/3,115 |
| BPS | $-3.78 | US—/3,115 |
Company Info
Hemab Therapeutics Holdings, Inc. is a clinical-stage biotechnology firm dedicated to transforming the treatment of blood coagulation disorders. Operating in the United States and Denmark, its mission is to enhance life and resilience for patients through innovative therapies. The company's leading pipeline candidate is HMB-001, a bispecific antibody. This asset is currently undergoing Phase 1/2 clinical trials for the preventive management of Glanzmann thrombasthenia and has progressed to Phase 2 for the prophylactic treatment of Factor VII deficiency. Additionally, Hemab is advancing HMB-002, a monovalent antibody, through Phase 1/2 clinical development. This drug is designed for the subcutaneous prophylactic treatment of Von Willebrand disease. Beyond these clinical assets, the company actively pursues numerous preclinical and discovery-stage programs. Established in 2020, Hemab Therapeutics Holdings, Inc. maintains its headquarters in Cambridge, Massachusetts.